Earnings Update: Sinopharm Group Co. Ltd. (HKG:1099) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Last week, you might have seen that Sinopharm Group Co. Ltd. (HKG:1099) released its annual result to the market. The early response was not positive, with shares down 2.2% to HK$19.96 in the past wee

Simply Wall StMar 26 18:29 ET

SINOPHARM GROUP CO. LTD. To Go Ex-Dividend On June 17th, 2024 With 0.12623 USD Dividend Per Share

March 26th - $SINOPHARM GROUP CO. LTD.(SHTDF.US)$ is trading ex-dividend on June 17th, 2024. Shareholders of record on June 18th, 2024 will receive 0.12623 USD dividend per share on August 13th, 2

moomoo NewsMar 25 20:45 ET

Guojin Securities: Innovative drugs are an important field for the implementation of scientific and technological progress. Overall, performance will rise simultaneously with market performance

Guojin Securities released a research report saying that global innovative drugs are an important field for realizing scientific and technological progress, and China's innovative drug industry chain is on the rise. With the full restoration of in-hospital diagnosis and treatment, the introduction of national incentives and support policies for innovative drugs one after another, and the pace of internationalization of Chinese pharmaceutical companies, the industry as a whole will usher in simultaneous improvements in performance and market performance. It is recommended to invest in two types of targets: 1) choose a racetrack, preferring domestic targets mapped by metabolic, neurological, and self-immune indications and cutting-edge innovators in overseas breakthroughs; 2) select leaders, which are optimistic about bottom-up and internationalization breakthroughs. Recommended attention: Cinda Biotech (01801), Kangfang Biology

新浪港股Mar 13 03:14 ET

Sinopharm Group Co. Ltd.'s (HKG:1099) Stock Is Going Strong: Is the Market Following Fundamentals?

Sinopharm Group (HKG:1099) has had a great run on the share market with its stock up by a significant 17% over the last three months. Given that the market rewards strong financials in the long-term

Simply Wall StFeb 28 02:03 ET

Sinopharm Group Co. Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 53% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Sinopharm Group fair value estimate is HK$31.57 Sinopharm Group's HK$20.70 share price signals that it might be 34% undervalued Analyst pr

Simply Wall StFeb 14 22:02 ET

Investors Don't See Light At End Of Sinopharm Group Co. Ltd.'s (HKG:1099) Tunnel

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 10x, you may consider Sinopharm Group Co. Ltd. (HKG:1099) as an attractive investment with its 6.7x P/E r

Simply Wall StJan 15 17:23 ET